Pharmaceuticals

Dare Bioscience

Dare Bioscience released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 152.46 K (forecast USD 27 K), actual EPS USD -0.2099 (forecast USD -0.305)

Dare Bioscience to Release FY2026 Q1 Earnings on May 14 During-Market EST, Forecast Revenue USD 27K, EPS USD -0.305

Dare Bioscience released FY2025 earnings on March 26 During-Market (EST), actual revenue USD 1.03 M (forecast USD 771 K), actual EPS USD -1.1986 (forecast USD -1.65)

Dare Bioscience released FY2025 Q4 earnings on March 26 During-Market EST, actual revenue USD 1.024 M (forecast USD 765 K), actual EPS USD -0.1009 (forecast USD -0.42)

Dare Bioscience to Release FY2025 Annual Earnings Report on March 26 During-Market EST, Forecast Revenue USD 771 K, EPS USD -1.65

H.C. Wainwright Analyst Reiterates Buy Rating on Daré Bioscience

Dare Bioscience released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 6.517 K, actual EPS USD -1.2326

Dare Bioscience released FY2025 Q3 earnings on November 13 After-Market (EST), actual revenue USD 2.262 K (forecast USD 0), actual EPS USD -0.2799 (forecast USD -0.385)

Dare Bioscience to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 9.75K, EPS USD -0.385

Dare Bioscience released FY2025 Semi-Annual earnings on August 14 During-Market (EST), actual revenue USD 4.255 K, actual EPS USD -0.9522

Dare Bioscience released FY2025 Q2 earnings on August 14 During-Market (EST), actual revenue USD -21.17 K (forecast USD 141.5 K), actual EPS USD -0.4527 (forecast USD -0.58)

Dare Bioscience to Release FY2025 Q2 Earnings on August 14 During-Market EST, Forecast Revenue USD 141.5K, EPS USD -0.58

Daré Bioscience Announces Positive Mid-Stage Results for Ovaprene Phase 3 Trial

Dare Bioscience's Annual Meeting Approves Director Elections and Accounting Firm Appointment

Dare Bioscience released FY2025 Q1 earnings on May 13 During-Market EST, actual revenue USD 25.43 K (forecast USD 0), actual EPS USD -0.4998 (forecast USD -0.58)

Dare Bioscience to Release Q1 2025 Earnings Report

Dare Bioscience Expects Quarterly Earnings Loss of 58 Cents Per Share

Dare Bioscience to release FY2025 Q1 earnings on May 13 During-Market EST, forecast revenue USD 0, EPS USD -0.58

Dare Bioscience Inc Posts Expected Quarterly Loss of 58 Cents Per Share

Dare Bioscience Inc Reports Fiscal Results for 2024 and Expects to Start Recording Revenue and Cash Flow in Q4

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

DARE

LABU

Dare Bioscience shares are trading lower after the company reported worse-than-expected Q1 sales results.

benzinga_article

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

SBIO

Dare Bioscience (NASDAQ:DARE) reported its Q1 2026 financial results, highlighting cash reserves of approximately $18.5 million and reliance on non-dilutive funding sources. The company is set to launch new products, including a topical cream for women's sexual health and a vaginal probiotic, with commercial activities starting in June 2026. Positive interim results from the Phase 3 trial of Ovaprene, a hormone-free contraceptive, were noted, and the company plans to engage with the FDA. Dare aims to generate revenue from multiple products, with a focus on innovative women's health solutions.

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

Ark Genomic Revolution ETF

iShares US Pharma

iShares Global Healthcare

Dare Bioscience Q1 2026 Earnings Call: Complete Transcript

SHPH

WGRX

PIII

ACOG

HCWB

In Thursday's after-market session, HCW Biologics saw a significant gain of 70.3%, reaching $0.57, following the release of Q1 earnings. Other notable gainers included P3 Health Partners (+47.14%), Alpha Cognition (+10.73%), and Shuttle Pharmaceuticals (+9.64%). Conversely, Dare Bioscience experienced the largest decline at 30.1%, with other losers including Aardvark Therapeutics (-15.16%) and Wellgistics Health (-10.11%). All companies reported Q1 earnings today, impacting their stock performance.

Shuttle Pharmaceuticals

P3 Health Partners

Alpha Cognition

HCW Biologics

Voyager Therap

Avita Medical

Aardvark Therapeutics

Zentek

Co-Diagnostics

Akanda

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's After-Market Session

Dare Bioscience, Inc. (NASDAQ:DARE) shares rose 5.95% to $2.67 following positive Phase 3 interim results for Ovaprene, a hormone-free contraceptive. The independent Data Safety Monitoring Board (DSMB) confirmed the trial could proceed without changes, showing a pregnancy rate of approximately 9% among participants. The stock is trading 7.1% above its 20-day SMA of $2.49, indicating a bullish trend, with key resistance at $2.75 and support at $2.49.

iShares US Medical Devices

SPDR S&P Health Equip

Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

Dare Bioscience fell 15.90%; Novo Nordisk rose 2.69%, with a transaction volume of USD 881 million; Eli Lilly fell 0.09%, with a transaction volume of USD 849 million; Johnson & Johnson fell 1.08%, with a transaction volume of USD 434 million; AstraZeneca rose 1.67%, with a market value of USD 285.8 billion

Price Alert

Novo Nordisk AS

Eli Lilly

Johnson & Johnson

AstraZeneca

U.S. stock market midday update: Dare Bioscience down 15.90%, trading volume increased, market sentiment fluctuations attract attention

Daré Bioscience, Inc. has updated its corporate investor presentation, available on its website and as part of a regulatory filing. The materials are for informational purposes only and not filed under U.S. securities laws. The latest analyst rating for DARE stock is a Buy with an $8.00 price target, but Spark's AI Analyst rates it as Neutral due to weak financial performance and funding risks. Daré focuses on women's health and engages with investors through regular updates.

Tip Ranks

Daré Bioscience Posts Updated Corporate Investor Presentation Online